Aclaris Therapeutics

Aclaris Therapeutics Announces Leadership Shake-up and Strategic Review, Investors Watch Closely

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a biopharmaceutical company specializing in dermatological treatments, has announced significant changes to its leadership and an impending strategic review of its business …

Aclaris Therapeutics Announces Leadership Shake-up and Strategic Review, Investors Watch Closely Read More
Aclaris Therapeutics

Aclaris Therapeutics Announces Promising Phase 2b Results for ATI-1777, Boosting Investor Confidence

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has released promising top-line results from its Phase 2b study of ATI-1777, a topical “soft” JAK 1/3 inhibitor developed for treating mild …

Aclaris Therapeutics Announces Promising Phase 2b Results for ATI-1777, Boosting Investor Confidence Read More

Aclaris Therapeutics

Aclaris Therapeutics Advances ATI-1777 into Phase 2b Trial, Plans Workforce Reduction to Preserve Capital

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is making strategic moves, announcing several updates this week including promising trial results, a shift in drug development focus, and a significant …

Aclaris Therapeutics Advances ATI-1777 into Phase 2b Trial, Plans Workforce Reduction to Preserve Capital Read More
Aclaris Therapeutics

Aclaris Therapeutics and Sun Pharma Sign Exclusive Patent License Agreement for Alopecia Treatment

WAYNE, PA — Aclaris Therapeutics, Inc., a Pennsylvania-based biopharmaceutical company, announced this week that it has entered into an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma). …

Aclaris Therapeutics and Sun Pharma Sign Exclusive Patent License Agreement for Alopecia Treatment Read More

Aclaris Therapeutics

Aclaris Therapeutics Halts Development of Rheumatoid Arthritis Drug After Phase 2b Study Misses Primary Endpoint

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) this week announced disappointing top-line results from a Phase 2b study of zunsemetinib (ATI-450) in patients with moderate to severe rheumatoid arthritis …

Aclaris Therapeutics Halts Development of Rheumatoid Arthritis Drug After Phase 2b Study Misses Primary Endpoint Read More